{"organizations": [], "uuid": "e125d160bb8d579900d9648158b7c5b16d277673", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180111.html", "section_title": "Archive News &amp; Video for Thursday, 11 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-puma-biotechnology-intends-to-modi/brief-puma-biotechnology-intends-to-modify-characteristics-summary-in-neratinib-marketing-authorization-application-idUSFWN1P60Z1", "country": "US", "domain_rank": 408, "title": "BRIEF-Puma Biotechnology Intends To Modify Characteristics Summary In Neratinib Marketing Authorization Application", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.994, "site_type": "news", "published": "2018-01-12T05:20:00.000+02:00", "replies_count": 0, "uuid": "e125d160bb8d579900d9648158b7c5b16d277673"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-puma-biotechnology-intends-to-modi/brief-puma-biotechnology-intends-to-modify-characteristics-summary-in-neratinib-marketing-authorization-application-idUSFWN1P60Z1", "ord_in_thread": 0, "title": "BRIEF-Puma Biotechnology Intends To Modify Characteristics Summary In Neratinib Marketing Authorization Application", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "puma biotechnology inc", "sentiment": "negative"}, {"name": "puma", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "neratinib", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 11 (Reuters) - Puma Biotechnology Inc:\n* PUMA BIOTECHNOLOGY INC SAYS IT MET WITH COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SCIENTIFIC ADVISORY GROUP ON ONCOLOGY\n* PUMA BIOTECHNOLOGY SAYS IT INTENDS TO MODIFY SUMMARY OF PRODUCT CHARACTERISTICS IN ITS MARKETING AUTHORIZATION APPLICATION FOR NERATINIB\n* PUMA BIOTECHNOLOGY SAYS TO MODIFY SUMMARY FOR NERATINIB TO FURTHER REFINE INTENDED POPULATION TO PATIENTS AT A HIGH RISK OF DISEASE RECURRENCE Source text: ( bit.ly/2D21ru9 ) Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://bit.ly/2D21ru9", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-12T05:20:00.000+02:00", "crawled": "2018-01-12T18:43:15.006+02:00", "highlightTitle": ""}